STXS Stereotaxis

Stereotaxis to Report First Quarter 2020 Financial Results on May 5, 2020

Stereotaxis to Report First Quarter 2020 Financial Results on May 5, 2020

ST. LOUIS, April 30, 2020 (GLOBE NEWSWIRE) -- (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 first quarter on Tuesday, May 5, 2020 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.

What: Stereotaxis first quarter financial results conference call
   
When: Tuesday, May 5, at 10:00 a.m. Eastern Time (7:00 a.m. PT)
   
Dial In Number: To access the live call, dial (US and Canada) or (International) and give the participant pass code 9794597.
   
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at
   
Call Replay: A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through May 12, 2020. To access a replay of the conference call, dial 1-855-859-2056 (US and Canada) or 1-404-537-3406 (International) and give the participant pass code 9794597.



About Stereotaxis

is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit .

Company Contacts:

David L. Fischel

Chairman and Chief Executive Officer

Kimberly Peery

Chief Financial Officer

314-678-6100

EN
30/04/2020

Underlying

STXSStereotaxis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Reports 2025 Second Quarter Financial Results ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with bro...

August 7, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia pat...

July 28, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Report Second Quarter 2025 Financial Results on August ...

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025 ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2025 financial results conferenc...

July 23, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Announces $12.5 Million Registered Direct Offering of Comm...

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at...

July 17, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

First Clinical Results from MAGiC Catheter Study Published in the Jour...

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is the first peer-reviewed literature s...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch